Adult nodular lymphocyte-predominant Hodgkin lymphoma: treatment modality utilization and survival

Cancer Medicine
Clayton AlonsoDaniel M Trifiletti

Abstract

Early-stage nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is associated with a favorable prognosis. Our aim was to evaluate the patterns of care of radiotherapy utilization in this disease and to define the relationship between treatment modality and survival. The National Cancer Database was queried for patients with stages I-II NLPHL diagnosed from 2004 to 2012. Patients were compared based on primary therapy into four categories: radiotherapy, chemotherapy, both, or neither. Covariate-adjusted and propensity score-weighted (PS) Cox proportional hazards models were used, adjusting for potential factors confounding survival. After exclusions, 1420 patients were evaluated, 571 (40%) received radiotherapy alone, 318 (22%) received chemotherapy alone, 351 (25%) received both, and 180 (13%) received neither. Younger patient age (P = 0.001), female gender (P = 0.019), and chemotherapy use (P < 0.001) were associated with decreased radiotherapy utilization. On PS, radiation alone (HR = 0.298, P < 0.001) and chemoradiotherapy (HR = 0.258, P < 0.001) were associated with improved survival compared to no upfront therapy, but the use of chemotherapy alone did not statistically differ compared to no initial therapy (HR = 0.784,...Continue Reading

References

Jul 17, 2009·The Oncologist·Alfred Ian Lee, Ann S LaCasce
Nov 26, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ronald C ChenPeter M Mauch
Nov 12, 2013·Blood·Ranjana H Advani, Richard T Hoppe
Feb 12, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ranjana H AdvaniNancy L Bartlett
Apr 13, 2015·International Journal of Radiation Oncology, Biology, Physics·Martin T KingRichard T Hoppe
Aug 5, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dennis A EichenauerAndreas Engert
Aug 19, 2015·International Journal of Radiation Oncology, Biology, Physics·Rahul R ParikhJoachim Yahalom
Oct 21, 2017·Clinical Lymphoma, Myeloma & Leukemia·Bismarck OdeiDavid K Gaffney

❮ Previous
Next ❯

Software Mentioned

R

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.